Teva beats first-quarter expectations but still has the same old problems
May 03, 2018 at 11:48 AM EDT
Teva had to make pricing concessions on its flagship multiple sclerosis drug Copaxone, and now expects a delay in approval of a key migraine drug, fremanezumab.
